1. Home
  2. CABA

CABA

Cabaletta Bio Inc.

Logo Cabaletta Bio Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-18-2024 3:30pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

Founded: 2017 Country:
United States
United States
Employees: N/A City: PHILADELPHIA
Market Cap: 785.9M IPO Year: 2019
Target Price: $33.88 AVG Volume (30 days): 950.2K
Analyst Decision: Strong Buy Number of Analysts: 8
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.65 EPS Growth: N/A
52 Week Low/High: $7.69 - $26.35 Next Earning Date: 05-09-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: